Is Inozyme Pharma, Inc. (INZY) a Buy, Sell, or Hold?
Inozyme Pharma, Inc.
NASDAQ:INZY
$4 USD
$0.01 (0.25%)
- Volume
- 1.46M
- Average Volume
- 2.21M
- Market Capitalization
- $258.25M
- P/E Ratio
- -2.47
- Dividend Yield
- 0.00%
- Price Target
- $14.00
- Year High
- $6.24
- Year Low
- $0.72
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $3.56
Industry, Sector & symbol
| Stock Exchange | NASDAQ |
| CEO | Douglas A. Treco |
| Industry | Biotechnology |
| Sector | Healthcare |
| Current Symbol | INZY |
| CUSIP | 45790W108 |
| CIK | 0001693011 |
| Web | https://www.inozyme.com |
| Phone | 857 330 4340 |
| Currency | USD |
| Employees | 67 |
| Country | US |
Liquidity
| Debt-to-Equity Ratio | 0.81 |
| Payout Ratio | 0.00 |
| Current Ratio | 3.56 |
| Quick Ratio | 3.56 |
| Cash Ratio | 0.62 |
Sales & Book Value
| Annual Sales | $- |
| Price / Sales | 0.00 |
| Cash Flow | -1.46 |
| Price / Cash Flow | -2.81 |
| Price / Book | 4.34 |
Price Target and Rating
| Average Stock Price Forecast | $14.00 |
| High Stock Price Forecast | $16.00 |
| Low Stock Price Forecast | $4.00 |
| Forecast Upside/Downside | -71.43% |
| Consensus Rating | N/A |
| Rating Score(0-5) | 0 |
| Research Coverage | 9 Analysts |
Profitability
| EPS (Most Recent Fiscal Year) | $-1.62 |
| Trailing P/E Ratio | -2.47 |
| PEG Ratio | 0.12 |
| P/E Growth | 0.12 |
| Net Income | $-102.02M |
| Net Margin | 0.00% |
| Pretax Margin | 0.00% |
| Return on Equity | -102.90% |
| Return on Assets | -82.82% |
Financials Score
| AltmanZ Score | -6.54 |
| Piotroski Score | 2.00 |
| Working Capital | 50.86M |
| Total Assets | 95.16M |
| Ebit | -101.08M |
| Market Cap | 258.25M |
| Total Liabilities | 63.37M |
Poll Results
About Inozyme Pharma, Inc. (NASDAQ:INZY) Stock
Inozyme Pharma, Inc. operates as a biopharmaceutical entity dedicated to addressing rare diseases. Its primary mission involves pioneering treatments for disorders characterized by aberrant mineralization, which impacts the body's vascular system, soft tissues, and skeletal structure. The company's flagship therapeutic candidate, INZ-701, is an engineered, soluble protein under development to combat specific genetic conditions, namely ENPP1 and ABCC6 deficiencies, as well as for the management of calciphylaxis. Inozyme maintains a licensing arrangement with Yale University concerning particular therapeutic and preventative agents. Established in 2015, the firm's main offices are situated in Boston, Massachusetts. ...
Frequently Asked Questions
-
What is the current Inozyme Pharma, Inc. (INZY) stock price?
-
Inozyme Pharma, Inc.(NASDAQ:INZY) stock price is $4 in the last trading session. During the trading session, INZY stock reached the peak price of $6.24 while $0.721 was the lowest point it dropped to. The percentage change in INZY stock occurred in the recent session was 0.25% while the dollar amount for the price change in INZY stock was $0.01.
-
INZY's industry and sector of operation?
-
The NASDAQ listed INZY is part of Biotechnology industry that operates in the broader Healthcare sector.
-
Who are the executives of INZY?
-
Douglas A. Treco | Chief Executive Officer & Chairman
Petra Duda | Chief Medical Officer
Matthew Winton | Senior Vice President & Chief Operating Officer
Axel Bolte | Co-Founder, Senior Advisor & Director
Kurt C. Gunter | Senior Vice President & Chief Medical Officer -
How many employees does INZY have?
-
Number of INZY employees currently stands at 67. INZY operates from 321 Summer Street, Boston, MA 02210, US.
-
Link for INZY official website?
-
Official Website of INZY is: https://www.inozyme.com
-
How do I contact INZY?
-
INZY could be contacted at phone #857 330 4340 and can also be accessed through its website. INZY operates from 321 Summer Street, Boston, MA 02210, US.
-
How many shares of INZY are traded daily?
-
The average number of INZY shares traded daily for last 3 months was 2.21M.
-
What is the market cap of INZY currently?
-
The market value of INZY currently stands at $258.25M with its latest stock price at $4